Compare Rocket Lab USA Inc (RKLB) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Select Medical Holdings Corporation — how do they compare? Rocket Lab USA Inc trades at $69.31 (market cap $43.19B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Rocket Lab USA Inc is far larger — about 21.1× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| RKLB | SEM | |
|---|---|---|
Market Cap | $43.19B | $2.05B |
Sector | Technology | Health |
52-Week High | $150.23 | $16.66 |
52-Week Low | $39.48 | $11.77 |
Enterprise Value | $41.94B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, with a bearish technical signal despite oscillators suggesting oversold conditions. The company reported a net loss of $198.21 million in 2025, though revenue grew to $601.80 million. Recent positive news includes a $266 million defense contract awarded on July 21, 2026, per Benzinga, providing a near-term catalyst amid broader sector volatility.
The outlook remains high-risk with negative profitability but strong analyst support; 75% recommend Buy with a $116.90 consensus target. Key risks include execution delays on the Neutron rocket and intense competition. Upside depends on contract execution and path to profitability, while downside stems from cash burn and market sentiment shifts.
Select Medical (SEM) trades at $16.51, unchanged on the day, amid a completed acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock shows a bullish technical signal with support and resistance clustered around $17. Financially, the company reported 2025 revenue of $5.45B and net income of $146.22M, with a P/E of 15.43 and P/S of 0.36 indicating moderate valuation. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into the board's fiduciary duties posing a key risk. Analyst sentiment is mixed with 35.71% buy ratings but 57.15% hold, reflecting uncertainty post-buyout. Investors should note the stock's limited movement potential given the acquisition price, with fundamental performance and legal outcomes driving any residual value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
